INS and type 2 diabetes mellitus: Clinical trials have validated the favorable outcomes of equol and its precursors, particularly in postmenopausal women with type 2 diabetes, leading to a significant decrease in fasting insulin levels, enhanced insulin sensitivity, and sustained blood glucose stability over the long term (Jayagopal et al. 2002).